

Cholinesterase, Serum, with Dibucaine Inhibition

Order Name: **PSEUDO/DI**

Test Number: 3608550

Revision Date: 12/12/2022

TEST NAME	METHODOLOGY	LOINC CODE
Cholinesterase Serum	Kinetic Spectrophotometric	2098-2
Dibucaine Number % inhibition		39354-6

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	1 mL	Serum	Clot Activator SST	Room Temperature
Instructions	Specimen Type: Gel-Barrier Tube Specimen Stability: Ambient: Not Available, Refrigerated : Not Available, Frozen: Not Available			

GENERAL INFORMATION	
Testing Schedule	Fri
Expected TAT	2-9 days
Clinical Use	The Pseudocholinesterase phenotype can be determined by analysis of Pseudocholinesterase and the percent inhibition by Dibucaine. Approximately 96% of the population has normal activity, approximately 4% will exhibit decreased activity that leads to prolonged paralysis following use of succinylcholine, and 1 in 3000 patients will exhibit severe , prolonged paralysis following anesthetic exposure.
Performing Labcorp Test Code	302107
Notes	Labcorp Test Code: 302107
CPT Code(s)	82480; 82638
Lab Section	Reference Lab